



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Lalruatadika Varte, Drugs Inspector
Office of the Chief Medical Officer
Kolasib, Mizoram- 796082
2. Serial No. and date of Inspector's memorandum : KLB/16/2025/IPA/DRUGS , 03-MAR-2025
3. Number of Sample : NIL
4. Date of receipt : 10-MAR-2025
5. Names of drugs purporting to be contained in the sample : Diclofenac Sodium Tablets I.P. 50 mg (Vovespan-50)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0447	GUW/LS/2025-26/451	SPT-34449	Jan-2023 Dec-2025	NA	Shervotec Pharmaceuticals, Plot No 82/4 & 82/5, HPSIDC Baddi, Distt. Solan (H.P.) -173205

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 07-May-2025 To 01-Jul-2025

COMPOSITION : Each film coated tablet contains: Diclofenac Sodium I.P. 50 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Brown colored, round, very slightly biconvex, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Diclofenac Sodium.	NA
3	Average weight	0.13544 gm	NA
4	Disintegration	Complies. Time taken for disintegration 8 minutes and 40 seconds.	NMT 30 minutes

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Diclofenac Sodium	52.5 mg/Tablet	50 mg/Tablet	105	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 07-JUL-2025

Rinku Kalita
GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

